Dr Li on the Rationale for Evaluating CG0070 Plus Pembrolizumab in BCG-Unresponsive NMIBC
August 7th 2023Roger Li, MD, expands on the mechanism of action for the combination of CG0070 and pembrolizumab, and discusses the rationale for investigating the regimen's synergy in patients with non–muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guérin.
Read More
Dr Li on the Use of CG0070 Plus Pembrolizumab in BCG-Unresponsive Non–muscle Invasive Bladder Cancer
April 29th 2023Roger Li, MD, discusses phase 2 data with the combination of CG0070 and pembrolizumab in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.
Read More